183 related articles for article (PubMed ID: 24595078)
21. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
22. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
[TBL] [Abstract][Full Text] [Related]
23. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
26. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
27. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
28. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
29. Nidogen-1: a candidate biomarker for ovarian serous cancer.
Li L; Zhang Y; Li N; Feng L; Yao H; Zhang R; Li B; Li X; Han N; Gao Y; Xiao T; Wu L
Jpn J Clin Oncol; 2015 Feb; 45(2):176-82. PubMed ID: 25378651
[TBL] [Abstract][Full Text] [Related]
30. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
Zhu YF; He LS; Zhang ZD; Huang QS
Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
[TBL] [Abstract][Full Text] [Related]
31. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
32. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
35. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
[TBL] [Abstract][Full Text] [Related]
36. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.
Ose J; Fortner RT; Rinaldi S; Schock H; Overvad K; Tjonneland A; Hansen L; Dossus L; Fournier A; Baglietto L; Romieu I; Kuhn E; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Masala G; Sieri S; Tumino R; Sacerdote C; Mattiello A; Ramon Quiros J; Obón-Santacana M; Larrañaga N; Chirlaque MD; Sánchez MJ; Barricarte A; Peeters PH; Bueno-de-Mesquita HB; Onland-Moret NC; Brändstedt J; Lundin E; Idahl A; Weiderpass E; Gram IT; Lund E; Kaw KT; Travis RC; Merritt MA; Gunther MJ; Riboli E; Kaaks R
Int J Cancer; 2015 Jan; 136(2):399-410. PubMed ID: 24890047
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer.
Rice GE; Edgell TA; Autelitano DJ
J Exp Clin Cancer Res; 2010 Jun; 29(1):62. PubMed ID: 20525245
[TBL] [Abstract][Full Text] [Related]
38. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.
Labrie M; De Araujo LOF; Communal L; Mes-Masson AM; St-Pierre Y
Sci Rep; 2017 Oct; 7(1):13244. PubMed ID: 29038585
[TBL] [Abstract][Full Text] [Related]
39. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract][Full Text] [Related]
40. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
